SectorBiological Technology
Established Date29/01/2021
Listing Date28/06/2024
ExchangeNASDAQ Stock Exchange
Full-time Employees224
Fiscal Year Ends31/12
Security TypeCommon stock
Office address280 East Grand Avenue South San Francisco, California 94080
Business
IntroductionAlumis Inc., a Delaware corporation, was incorporated on January 29, 2021. They are a clinical-stage biopharmaceutical company initially focused on developing two tyrosine kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor they are developing to achieve maximum targeted inhibition, and A-005, a central nervous system osmotic molecule. The company's mission is to significantly improve patients' lives by replacing broad immunosuppression with targeted therapy.
